360
Participants
Start Date
June 30, 2002
Primary Completion Date
April 30, 2007
Study Completion Date
August 31, 2007
Therapeutic Drug Monitoring (TDM)
Beth Israel Medical Center, New York
Chelsea Clinic, New York
New York University - Bellevue, New York
Long Beach Memorial (Pediatric), New York
Columbia Univ, New York
SUNY-Buffalo (Rochester), Buffalo
Community Health Network Inc, Rochester
Univ of Rochester Medical Center, Rochester
Univ of Pittsburgh, Pittsburgh
Univ of Maryland, Institute of Human Virology, Baltimore
University of North Carolina, Chapel Hill
Duke Univ Med Ctr, Durham
Comprehensive Care Clinic, Nashville
Case Western Reserve Univ, Cleveland
Wishard Hosp, Indianapolis
The CORE Ctr, Chicago
Univ of Colorado Health Sciences Ctr, Denver
UCLA School of Medicine, Los Angeles
Univ of California, San Diego Antiviral Research Center (AVRC), San Diego
Univ of California San Francisco, San Francisco
Univ of Washington (Seattle), Seattle
Univ of Alabama at Birmingham, Birmingham
Univ of Southern California, Los Angeles
San Mateo County AIDS Program, Stanford
Santa Clara Valley Med Ctr, Stanford
Willow Clinic, Stanford
Univ of Miami, Miami
Univ of Hawaii, Honolulu
Northwestern Univ, Chicago
Methodist Hosp of Indiana, Indianapolis
Indiana Univ Hosp, Indianapolis
Johns Hopkins Univ, Baltimore
Harvard (Masschusetts General Hosp), Boston
Beth Israel Deaconess-West Campus, Boston
Brigham and Women's Hosp, Boston
Univ of Minnesota, Minneapolis
St. Louis Connect Care, St Louis
Washington Univ (St. Louis), St Louis
Ohio State Univ, Cincinnati
Univ of Cincinnati, Cincinnati
Cleveland Clinic, Cleveland
MetroHealth Med Ctr, Cleveland
Rhode Island Hosp, Providence
Stanley Street Treatment and Resource, Providence
The Miriam Hosp, Providence
Univ of Texas, Galveston, Galveston
University of Puerto Rico, San Juan
National Institute of Allergy and Infectious Diseases (NIAID)
NIH